Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 2.7M | 26% |
| Gross Profit | 2.1M | 35.9% |
| Cost of Revenue | 600,000 | 0% |
| Operating expense | 194M | 9.4% |
| Net Income | -162M | 120.6% |
| EBITDA | -153M | 206.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 665M | 16.3% |
| Total Liabilities | 1.88B | 0.4% |
| Shares Outstanding | 189M | 0.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -181M | 341.7% |
| Cash from investing | 38M | 1157.8% |
| Cash from financing | 710,000 | 112.3% |
EPS
Financial Highlights for BridgeBio Pharma in Q3 '24
BridgeBio Pharma reported a revenue of 2.7M, which is a 26% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.1M, marking a 35.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 600,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 194M, showing a 9.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -162M, showing a -120.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -153M, showing a -206.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
BridgeBio Pharma faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
